Topics

All Topics

On the Road

Major Medical

Protecting Your Family

In the Workplace

Workplace Injuries

Miscellaneous

Miscellaneous

Skin Patch Approved for ADHD

Jamie Sheller

Attorney
(866) 735-1102 Ext 475

Posted by Jamie ShellerApril 25, 2006 9:17 AM

Tags: Drug Products

0 Comments

Print Article

Shire PLC recently announced that the FDA had approved a new drug product, the first skin patch to treat attention deficit hyperactivity disorder. The patch is called Daytrana, and will be available in June or July. Daytrana is recommended to be worn for nine hours. One claimed advantage of the drug patch is that doctors can more easily manage dosage and possible side effects, by having children wear it for less than the recommended daily time. In trials, the patch was shown to improve overall symptoms of ADHD. However, side effects of the drug included insomnia, weight loss, mood swings, tic, nausea, vomiting and decreased appetite.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Philadelphia

Keep up with the latest updates using your favorite RSS reader

Legal Assistance Center

More Info

Sheller, P.C. (866) 735-1102 Ext 475 www.sheller.com

Jamie Sheller
(866) 735-1102 Ext 475 Email Jamie

Personal Injury Lawyers Serving: Statewide Pennsylvania, Philadelphia, Norristown, Cheltenham, Chester, Drexel Hill, Folsom, Havertown, King of Prussia, Levittown, Radnor, Springfield, Swarthmore, West Chester, Willow Grove

1528 Walnut Street3rd Floor, Philadelphia, Pennsylvania 19102 [ Show Map ]

First Name

Last Name

Phone

Zip

Better Business Bureau Accredited Business

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.